Resisting cell death and preventing apoptosis is one of the hallmarks of cancer [19], and targeting therapy resistance through BCL-2 inhibition may be a potential successful therapeutic approach to induce apoptosis in AML cells. This evidence concerns the gene BCL2 and acute myeloid leukemia.